WHC is still in active development. Read this to understand our approach.
depiction of CSMVOZKEWSOFER-UHFFFAOYSA-N.svg
isomerdesign

Cebranopadol

Verificar en isomerdesign

drugmap

GRT-6005

Verificar en drugmap

wiki

Cebranopadol

Verificar en wiki

Data

InChI: InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3

Sinónimos: Cebranopadol (USAN/INN), ZINC3950145, CHEMBL3962932, AKOS025290738, NCGC00378895-01,GRT-6005, CS-1323, CHEMBL2364605, AK170452, BDBM177926, SB16531, BCP09612,Cebranopadol, GRT6005, AKOS032953927, SCHEMBL14183935, HY-15536, AS-35183, GRT 6005, EX-A1095, DB12830, 863513-91-1, GTPL8866, BDBM50101095, 7GDW9S3GN3, Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal, SCHEMBL10035739, SCHEMBL19336241, UNII-7GDW9S3GN3, SCHEMBL154336, AKOS025402576, MolPort-039-063-422, BDBM50101112, GRT 6005/06, SCHEMBL566256, Cebranopadol [USAN:INN], Cebranopadol(GRT-6005), CHEMBL3545616

Estimated data

Solubilidad: -5.207 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 32.4% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.